الصفحة الرئيسية>>Signaling Pathways>> Neuroscience>> Neurokinin Receptor>>Fezolinetant (ESN-364)

Fezolinetant (ESN-364)

رقم الكتالوجGC30104

Fezolinetant (ESN-364) هو مضاد لمستقبلات Neurokinin 3 (NK3R) ، ويستخدم لعلاج الهبات الساخنة بعد انقطاع الطمث.

Products are for research use only. Not for human use. We do not sell to patients.

Fezolinetant (ESN-364) التركيب الكيميائي

Cas No.: 1629229-37-3

الحجم السعر المخزون الكميّة
10mM (in 1mL DMSO)
277٫00
متوفر
1mg
101٫00
متوفر
5mg
351٫00
متوفر
10mg
513٫00
متوفر
25mg
1026٫00
متوفر
50mg
1638٫00
متوفر
100mg
2652٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

Fezolinetant is an antagonist of the neurokinin 3 receptor (NK3R), used for the treatment of menopausal hot flushes.

Fezolinetant (ESN364, 1 mg/kg, iv bolus) reversibly inhibits the regular, pulsatile secretion of LH in the ovarectomized ewe. ESN364 represses the pulse pattern of LH in all treated animals. ESN364 (5 mg/kg, p.o.) lowers plasma LH, but not FSH, in the castrated monkey. ESN364 (10, 25, 50 mg/kg, orally) also blocks the LH surge and decreases ovarian hormone levels throughout the menstrual cycle in monkeys[1].

[1]. Fraser GL, et al. The NK3 Receptor Antagonist ESN364 Interrupts Pulsatile LH Secretion and Moderates Levels of Ovarian Hormones Throughout the Menstrual Cycle. Endocrinology. 2015 Nov;156(11):4214-25.

مراجعات

Review for Fezolinetant (ESN-364)

Average Rating: 5 ★★★★★ (Based on Reviews and 11 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Fezolinetant (ESN-364)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.